Bunyaratavej Sumanas, Leeyaphan Charussri, Rujitharanawong Chuda, Surawan Theetat M, Muanprasat Chanai, Matthapan Lalita
a Department of Dermatology , Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok , Thailand.
J Dermatolog Treat. 2016 Aug;27(4):359-63. doi: 10.3109/09546634.2015.1109029. Epub 2015 Nov 11.
Amorolfine nail lacquer was mentioned as an effective treatment for non-dermatophyte nail infection. Onychomycosis that caused by Neoscytalidium dimidiatum is considered recalcitrant onychomycosis.
This study aimed to demonstrate efficacy and treatment outcomes of amorolfine nail lacquer in N. dimidiatum onychomycosis, compared with topical urea treatment.
This was a retrospective study of patients daiagnosed as N. dimidiatum onychomycosis at dermatologic clinic between April 2010 and August 2014. Clinical manifestations and laboratory results were collected. The evaluation included 50% improvement, which meant 50% decrease in subungual hyperkeratosis thickness from original untreated nails. Mycological cure is defined by negative result of both KOH and fungal culture. Moreover, complete cure means infected nails return to its normal condition as well as KOH and fungal culture yield negative results.
Among 53 outpatients of N. dimidiatum infection, 28 (52.8%) were treated by amorolfine nail lacquer and other 26 (47.2%) by conventional topical urea cream with occlusion. Comparison between amorolfine and topical urea groups, mycological cure rate was significantly shown in amorolfine group (89.3% vs. 32%; p < 0.0001). Moreover, 50% clinical improvement and complete cure rate of amorolfine group were significantly higher than those of topical urea group (85.7% vs. 48%; p = 0.003 and 50% vs. 20%; p = 0.023, respectively). Median time to mycological cure and complete cure in amorolfine group was significantly shorter than that of topical urea group (p = 0.001 and p = 0.013, respectively).
This study supported that amorolfine nail lacquer provided promising efficacy in the treatment of Neoscytalidium onychomycosis as a novel monotherapy regimen which were superior to topical urea cream with occlusion in every aspect.
阿莫罗芬搽剂被提及可有效治疗非皮肤癣菌性甲感染。由双间新暗色柱节孢引起的甲真菌病被认为是顽固性甲真菌病。
本研究旨在证明与外用尿素治疗相比,阿莫罗芬搽剂治疗双间新暗色柱节孢甲真菌病的疗效和治疗结果。
这是一项对2010年4月至2014年8月在皮肤科诊所被诊断为双间新暗色柱节孢甲真菌病的患者进行的回顾性研究。收集临床表现和实验室结果。评估包括50%改善,即与未经治疗的原始指甲相比,甲下过度角化厚度减少50%。真菌学治愈定义为KOH和真菌培养结果均为阴性。此外,完全治愈意味着感染的指甲恢复正常状态以及KOH和真菌培养结果均为阴性。
在53例双间新暗色柱节孢感染的门诊患者中,28例(52.8%)接受阿莫罗芬搽剂治疗,另外26例(47.2%)接受传统外用尿素乳膏封包治疗。阿莫罗芬组和外用尿素组比较,真菌学治愈率在阿莫罗芬组显著更高(89.3%对32%;p<0.0001)。此外,阿莫罗芬组的50%临床改善率和完全治愈率显著高于外用尿素组(分别为85.7%对48%;p=0.003和50%对20%;p=0.023)。阿莫罗芬组真菌学治愈和完全治愈的中位时间显著短于外用尿素组(分别为p=0.001和p=0.013)。
本研究支持阿莫罗芬搽剂作为一种新型单一疗法方案,在治疗双间新暗色柱节孢甲真菌病方面提供了有前景的疗效,在各方面均优于外用尿素乳膏封包治疗。